European Union - English - EMA (European Medicines Agency)

sandoz gmbh - infliximab - arthritis, psoriatic; psoriasis; crohn disease; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosuppressants - treatment of rheumatoid arthritis, crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - infliximab 100mg;   - powder for injection - 100 mg - active: infliximab 100mg   excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate monohydrate polysorbate 80 sucrose - rheumatoid arthritis inflectra is a ?disease-controlling anti-rheumatic therapy" (dcart) indicated for: · the reduction of signs and symptoms · prevention of structural joint damage (erosions and joint space narrowing) · improvement in physical function in patients with active disease. inflectra should be given in combination with methotrexate.

European Union - English - EMA (European Medicines Agency)

janssen biologics b.v.  - infliximab - spondylitis, ankylosing; arthritis, rheumatoid; psoriasis; crohn disease; arthritis, psoriatic; colitis, ulcerative - immunosuppressants - rheumatoid arthritisremicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:adult patients with active disease when the response to disease-modifying antirheumatic drugs (dmards), including methotrexate, has been inadequate;adult patients with severe, active and progressive disease not previously treated with methotrexate or other dmards.in these patient populations, a reduction in the rate of the progression of joint damage, as measured by x-ray, has been demonstrated.adult crohn's diseaseremicade is indicated for:treatment of moderately to severely active crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies;treatment of fistulising, active crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).paediatric crohn's diseaseremicade is indicated for treatment of severe, active crohn's disease, in children and adolescents aged six to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy.ulcerative colitisremicade is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.paediatric ulcerative colitisremicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged six to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-mp or aza, or who are intolerant to or have medical contraindications for such therapies.ankylosing spondylitisremicade is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.psoriatic arthritisremicade is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous dmard therapy has been inadequate.remicade should be administered:in combination with methotrexate;or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.remicade has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.psoriasisremicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultraviolet a (puva).

Canada - English - Health Canada

amgen canada inc - infliximab - powder for solution - 100mg - infliximab 100mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

celltrion healthcare co ltd - infliximab - kit - 120mg - infliximab 120mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

celltrion healthcare co ltd - infliximab - solution - 120mg - infliximab 120mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

janssen inc - infliximab - powder for solution - 100mg - infliximab 100mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

janssen inc - infliximab - powder for solution - 100mg - infliximab 100mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

pfizer canada ulc - infliximab - powder for solution - 100mg - infliximab 100mg

Canada - English - Health Canada

samsung bioepis co., ltd - infliximab - powder for solution - 100mg - infliximab 100mg - disease-modifying antirheumatic agents